Artelo Biosciences (NASDAQ:ARTL) Issues Quarterly Earnings Results

Artelo Biosciences (NASDAQ:ARTL) announced its quarterly earnings results on Thursday. The company reported ($4.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($3.22), FiscalAI reports.

Artelo Biosciences Price Performance

Shares of ARTL traded up $0.03 during trading hours on Thursday, hitting $2.34. 84,081 shares of the stock were exchanged, compared to its average volume of 2,318,749. Artelo Biosciences has a fifty-two week low of $2.30 and a fifty-two week high of $85.80. The business has a 50-day moving average of $4.94 and a 200-day moving average of $5.10. The firm has a market capitalization of $2.19 million, a P/E ratio of -0.04 and a beta of 0.05.

Analysts Set New Price Targets

ARTL has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Wall Street Zen cut Artelo Biosciences to a “strong sell” rating in a research note on Saturday, April 25th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.